Short term efficacy and safety outcomes after switching from Anti-CD20 DMTs to Cladribine in a real-world setting (5389)
2020; Lippincott Williams & Wilkins; Volume: 94; Issue: 15_supplement Linguagem: Inglês
10.1212/wnl.94.15_supplement.5389
ISSN1526-632X
AutoresDaniel I. O’Neill, Suzanne Hodgkinson,
Tópico(s)Advanced Breast Cancer Therapies
ResumoMonday, April 27April 14, 2020Free AccessShort term efficacy and safety outcomes after switching from Anti-CD20 DMTs to Cladribine in a real-world setting (5389)Daniel O’Neill and Suzanne HodgkinsonAuthors Info & AffiliationsApril 14, 2020 issue94 (15_supplement)https://doi.org/10.1212/WNL.94.15_supplement.5389 Letters to the Editor
Referência(s)